Quick Answer
SAB Biotherapeutics, Inc. reported Net Income of $13.27 million for fiscal year 2025.
SAB Biotherapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $13.27M | +138.9% |
| 2024 | -$34.11M | +19.2% |
| 2023 | -$42.19M | -125.1% |
| 2022 | -$18.74M | -9.3% |
| 2021 | -$17.14M | -185.2% |
| 2020 | $20.12M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $45.45M | +539.1% | +549.3% |
| June 30, 2025 | -$10.11M | -37.9% | -94.6% |
| March 31, 2025 | -$5.20M | -3.4% | +49.8% |
| September 30, 2024 | -$10.35M | -102.8% | -41.1% |
| June 30, 2024 | -$7.34M | -6.6% | -46.0% |
| March 31, 2024 | -$5.03M | +31.7% | +1.5% |
| September 30, 2023 | -$5.10M | +27.9% | +25.8% |
| June 30, 2023 | -$6.88M | -44.1% | +6.4% |
- SAB Biotherapeutics, Inc. showed an increase of +138.9% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, SAB Biotherapeutics, Inc.’s net income has declined by 34.0% (from $20.12 million to $13.27 million).
- The most recent figure is from SAB Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: